This protocol sets out measures for the follow-up and management of individuals exposed to infected animals and human cases of avian influenza, and for the public health management of possible and confirmed human cases.
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
This report which is part of the RAGIDA project (Risk Assessment Guidance for Infectious Diseases transmitted on Aircraft) provides viable options for decision-makers when faced with the choice of whether to contact trace air travellers and crew that were potentially exposed to infectious diseases during a flight.
In order to increase preparedness to respond to possible cases and clusters of Highly Pathogenic Avian Influenza A/H5N1 in humans in Europe, the ECDC has prepared a toolkit for the European Union member states.